MiMedx Group (NASDAQ:MDXG) Price Target Raised to $8.00 at Craig Hallum

Key Points

• Craig Hallum raised MiMedx Group’s price target to $8.00 from $6.00 and maintained a “buy” rating, implying 76.41% upside from the stock’s $4.54 price.
• Analyst sentiment is generally positive: six analysts rate MDXG a Buy and one rates it Sell, resulting in a consensus “Moderate Buy” rating and an $8.57 average price target.
• MiMedx reported quarterly revenue of $64.36 million, above expectations, while matching estimates with an EPS loss of $0.05; institutional investors own approximately 79.15% of the company.

MiMedx Group (NASDAQ:MDXG - Get Free Report) had its target price boosted by analysts at Craig Hallum from $6.00 to $8.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. Craig Hallum's price objective would indicate a potential upside of 76.41% from the company's current price.

A number of other analysts have also weighed in on MDXG. Citizens Jmp cut their price objective on shares of MiMedx Group from $7.00 to $6.00 and set a "market outperform" rating on the stock in a research note on Thursday, April 30th. Raymond James Financial set a $8.00 price objective on MiMedx Group in a report on Monday, August 17th. Weiss Ratings restated a "sell (d)" rating on shares of MiMedx Group in a research report on Thursday, August 13th. Cantor Fitzgerald restated an "overweight" rating and issued a $8.00 price objective on shares of MiMedx Group in a report on Monday, August 17th. Finally, Wall Street Zen lowered shares of MiMedx Group from a "hold" rating to a "sell" rating in a research note on Saturday, August 1st. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $8.57.

MiMedx Group Stock Up 2.6%

Shares of MDXG traded up $0.12 during mid-day trading on Thursday, hitting $4.54. 827,015 shares of the company traded hands, compared to its average volume of 1,303,525. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. MiMedx Group has a 1-year low of $3.03 and a 1-year high of $7.97. The company has a market capitalization of $661.02 million, a PE ratio of 113.40 and a beta of 1.45. The business has a 50 day moving average of $4.15 and a 200 day moving average of $4.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). The business had revenue of $64.36 million during the quarter, compared to analysts' expectations of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. Equities research analysts anticipate that MiMedx Group will post -0.1 EPS for the current year.

Institutional Trading of MiMedx Group

Several institutional investors have recently made changes to their positions in the company. Sunbelt Securities Inc. acquired a new position in shares of MiMedx Group in the 1st quarter valued at $42,000. E Fund Management Co. Ltd. acquired a new stake in shares of MiMedx Group during the 2nd quarter worth about $45,000. Syon Capital LLC purchased a new stake in MiMedx Group in the 2nd quarter valued at about $45,000. Legal & General Group Plc purchased a new stake in MiMedx Group in the 2nd quarter valued at about $45,000. Finally, Kemnay Advisory Services Inc. acquired a new position in MiMedx Group in the fourth quarter valued at about $48,000. Hedge funds and other institutional investors own 79.15% of the company's stock.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source